drugset
drugset / Trial / NCT03934684

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

NCT03934684 ↗

Phase 4 Completed 101 enrolled Amgen
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To characterize safety associated with the use of Kyprolis under the locally approved label.

Timeline

Start
2019-09-16
Primary completion
2023-03-23
Completion
2025-06-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Carfilzomib Other / unclassified 27 mg/m2 Other
Subject Carfilzomib Other / unclassified 56 mg/m2 Other
Subject Dexamethasone Small molecule 20 mg Oral
Subject Dexamethasone Small molecule 40 mg Oral
Subject Lenalidomide Other / unclassified 25 mg Oral

Indications

refractory plasma cell neoplasm